SCM
KRYS icon

Sterling Capital Management’s Krystal Biotech KRYS Stock Holding History

Sterling Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.8K Sell
91
-70
-43% -$20.9K ﹤0.01% 1685
2026
Q1 		$41.6K Sell
161
-1
-0.6% -$266 ﹤0.01% 1723
2025
Q4 		$39.9K Buy
162
+102
+170% +$21.5K ﹤0.01% 1884
2025
Q3 		$10.6K Hold
60
– – ﹤0.01% 2449
2025
Q2 		$8.25K Buy
60
+34
+131% +$4.99K ﹤0.01% 2251
2025
Q1 		$4.69K Buy
26
+1
+4% +$168 ﹤0.01% 2195
2024
Q4 		$3.92K Hold
25
– – ﹤0.01% 2561
2024
Q3 		$4.55K Buy
+25
New +$4.82K ﹤0.01% 1803

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sterling Capital Management's KRYS Position: Q2 2026 in Review

Sterling Capital Management reduced its Krystal Biotech (KRYS) stake by 43% in Q2 2026, selling an estimated $20.9K and leaving 91 shares worth $33.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1685.

Sterling Capital Management first reported a position in KRYS in Q3 2024 and has held it in 8 quarters since. The position peaked at $41.6K in Q1 2026. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Sterling Capital Management held 91 shares of Krystal Biotech worth $33.8K as of Q2 2026.
  • Sterling Capital Management sold 70 Krystal Biotech shares in Q2 2026, an estimated $20.9K.
  • Krystal Biotech made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1685 holding.
  • Sterling Capital Management first reported a position in Krystal Biotech in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Krystal Biotech position peaked at $41.6K in Q1 2026.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.